Seeking Alpha

Acadia Pharmaceuticals (ACAD +1.3%) says it receiving funding from Fast Forward, LLC, a...

Acadia Pharmaceuticals (ACAD +1.3%) says it receiving funding from Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA (MCGAY.PK). The funding will go to support R&D directed at using AC-186, ACAD’s estrogen receptor (ER)-beta agonist, as a new approach to the treatment of multiple sclerosis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector